Efficacy of Ezetimibe Is Not Related to NPC1L1 Gene Polymorphisms in a Pilot Study of Chilean Hypercholesterolemic Subjects

详细信息    查看全文

• 作者：Tomás Zambrano ; Nicolás Saavedra ; Fernando Lanas…
• 刊名：Molecular Diagnosis & Therapy
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：19
• 期：1
• 页码：45-52
• 全文大小：278 KB
• 参考文献：1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-45. CrossRef
  2. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993;34(10):1637-9.
  3. Lammert F, Wang DQ. New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology. 2005;129(2):718-4. CrossRef
  4. Jones PJ, Pappu AS, Hatcher L, Li ZC, Illingworth DR, Connor WE. Dietary cholesterol feeding suppresses human cholesterol synthesis measured by deuterium incorporation and urinary mevalonic acid levels. Arterioscler Thromb Vasc Biol. 1996;16(10):1222-. CrossRef
  5. Thurnhofer H, Hauser H. Uptake of cholesterol by small intestinal brush border membrane is protein-mediated. Biochemistry. 1990;29(8):2142-. CrossRef
  6. Hernandez M, Montenegro J, Steiner M, Kim D, Sparrow C, Detmers PA, et al. Intestinal absorption of cholesterol is mediated by a saturable, inhibitable transporter. Biochim Biophys Acta. 2000;1486(2-):232-2. CrossRef
  7. Clader JW. The discovery of ezetimibe: a view from outside the receptor. J Med Chem. 2004;47(1):1-. CrossRef
  8. Earl J, Kirkpatrick P. Fresh from the pipeline. Ezetimibe. Nat Rev Drug Discov. 2003;2(2):97-. CrossRef
  9. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation. 2003;107(25):3124-. CrossRef
  10. Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y, et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos. 2002;30(4):430-. CrossRef
  11. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-4. CrossRef
  12. Davis HR Jr, Zhu LJ, Hoos LM, Tetzloff G, Maguire M, Liu J, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem. 2004;279(32):33586-2. CrossRef
  13. Klett EL, Patel SB. Biomedicine. Will the real cholesterol transporter please stand up. Science. 2004;303(5661):1149-0. CrossRef
  14. van Heek M, Farley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 2001;134(2):409-7. CrossRef
  15. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201-. CrossRef
  16. Davies JP, Levy B, Ioannou YA. Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1. Genomics. 2000;65(2):137-5. CrossRef
  17. Carstea ED, Morris JA, Colem
• 刊物主题：Molecular Medicine; Human Genetics; Cancer Research; Laboratory Medicine; Pharmacotherapy;
• 出版者：Springer International Publishing
• ISSN：1179-2000

文摘

Background and Objective Niemann-Pick C1 Like 1 (NPC1L1) is a multi-transmembrane transport protein highly expressed in the small intestine. It mediates sterol transfer throughout the brush border membrane of enterocytes, becoming essential for intestinal cholesterol absorption and ensuing whole-body cholesterol homeostasis. This protein is targeted by ezetimibe, a potent cholesterol absorption inhibitor. Single nucleotide polymorphisms (SNPs) in NPC1L1 have been associated to variation in both plasma low-density lipoprotein (LDL) cholesterol levels and lipid-lowering medication with ezetimibe. However, there are no data evaluating the impact of NPC1L1 variants on Chilean subjects medicated with ezetimibe monotherapy. Therefore, we assessed the contribution of two unexplored NPC1L1 variants on plasma lipids and response to ezetimibe in Chilean hypercholesterolemic individuals. Methods Using PCR-restriction fragment length polymorphism (RFLP), we analyzed the SNP distribution of two common variants; ?33A>G (rs17655652) and 1679C>G (rs2072183), and their relation with plasma lipids and lipid-lowering response to ezetimibe in 60 hypercholesterolemic Chilean subjects. Results Genotype distribution for the rs17655652 variant was AA 57?%, 40?% AG and 3?% GG, whereas for the rs2072183 SNP was 57?% CC, 35?% CG and 8?% GG. Minor allele frequencies (MAFs) were 0.23 and 0.26, respectively. No association was observed between NPC1L1 SNPs and baseline cholesterol. After therapy, none of the polymorphisms affected ezetimibe response in the studied cohort (P?>?0.05). Conclusion Data obtained indicates that polymorphisms rs17655652 and rs2072183 were not related to cholesterol variability. Also, lipid-lowering response to ezetimibe is not impacted by the NPC1L1 polymorphisms studied in Chilean hypercholesterolemic subjects.